ABT vs OBIO
ABT: A diversified global health care leader focused on diagnostic, medical device, nutritional, and pharmaceutical solutions. OBIO: A clinical-stage biomedical company developing high-impact medical devices through a partnership-enabled business model that shares development risk and rewards with global medical device leaders.
Side-by-side fundamentals
| Metric | ABT | OBIO | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $98.49 | $5.73 | |
| Market cap | $171.6B | $344M | |
| P/E as of 2026-10-08 | 31.70 | n/a | |
| Net margin FY2025, SEC XBRL | +14.7% | -157.4% | ABT higher |
| Operating margin FY2025, SEC XBRL | +18.2% | -154.7% | ABT higher |
| ROE FY2025, SEC XBRL | +12.4% | -98.4% | ABT higher |
| ROA FY2025, SEC XBRL | +7.5% | -45.9% | ABT higher |
| Debt / equity as of 2026-09-03 | 0.64 | 0.28 | OBIO lower |
| Revenue growth (YoY) as of 2026-09-03 | +8.1% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +0.5% | +111.6% | OBIO higher |
| Dividend yield as of 2026-09-03 | +2.5% | n/a | |
| Dividend streak (yrs) SEC XBRL | 4 | 0 | ABT higher |
| Beta as of 2026-09-03 | 0.18 | 1.49 | |
| 1-year return as of 2026-10-08 close | -26.6% | +97.6% | OBIO higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.